Teva receives FDA priority review for Tourette drug
Share
Teva Pharmaceuticals (NYSE:TEVA) announced that the U.S. FDA accepted its New Drug Application for ecopipam (EBS-101) and granted Priority Review for pediatric Tourette syndrome.
Teva Pharmaceuticals (NYSE:TEVA) announced that the U.S. FDA accepted its New Drug Application for ecopipam (EBS-101) and granted Priority Review for pediatric Tourette syndrome.
Teva Pharmaceutical Industries (NYSE:TEVA) and Medincell announced Thursday that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, an investigational long-acting injectable formulation designed to treat adults living with schizophrenia.
Alvotech (NASDAQ:ALVO) and Teva (NYSE:TEVA) have secured a U.S. market entry date for their proposed biosimilar to Eylea® (aflibercept), AVT06, under a settlement agreement with Regeneron.
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) announced a major clinical victory on Tuesday, revealing that their investigational antibody, duvakitug (formerly TEV-574), successfully maintained disease control in patients with inflammatory bowel disease (IBD) for nearly a full year.
